Authors
Omar Hammoud, Maria George Elias, Amjad Slika, Aleen Khoury, Stephanie Mehanna, Joelle Abou Chacra, Selim Nasser, Janice R Aldrich-Wright, Costantine F Daher, Robin I Taleb
Published in
ACS omega. Volume 11. Issue 41. Pages 62402-62411. Oct 20, 2026. Epub Oct 07, 2026.
Abstract
This study investigates the chemotherapeutic potential of Pt II 5CLSS and Pt IV 5CLSS against breast cancer in vivo. Cell viability was assessed 72 h post-treatment, revealing potent cytotoxic activity with IC50 values of 0.447 μM for Pt II 5CLSS and 0.922 μM for Pt IV 5CLSS. Cellular uptake studies used ICP-MS to confirm active transport of both complexes into cells, showing significant accumulation in the nuclear/cytoskeletal fractions. A 28-day toxicity study in female Sprague-Dawley rats demonstrated that escalating doses up to 15 mg/kg (Pt II 5CLSS) and 30 mg/kg (Pt IV 5CLSS) caused no mortality nor adverse effects on liver and kidney function. In a chemically induced breast cancer rat model, both complexes significantly reduced tumor weight by 93-100% at doses of 1 and 5 mg/kg, with no observable nephrotoxicity or hepatotoxicity. Histopathological analysis confirmed the reduction or absence of tumors in the majority of the treated animals with Pt IV 5CLSS (1 mg/kg bw) being the most effective. Toxicity evaluation in sus scrofa pigs showed that Pt IV 5CLSS was well tolerated at both 1- and 2.5 mg/kg bw, with no mortality, behavioral changes, or signs of acute toxicity. Overall, both Pt II 5CLSS and Pt IV 5CLSS demonstrate strong antineoplastic activity against breast cancer with a favorable safety profile, supporting their potential as alternative platinum-based chemotherapeutic agents.
PMID:
42923595
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0